arrow
C

Cláudia Bertan

College of Technology and Agricultural Sciences
H指数:31
被引数:4,896

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Conjugated linoleic acid supplementation: Insights into prostaglandin synthesis and in vitro embryonic development

共轭亚油酸补充剂:前列腺素合成及体外胚胎发育的见解

2025-09-010
PRE
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Capivasertib联合恩扎鲁他胺治疗多西他赛和阿比曲酮治疗转移性去势抵抗性前列腺癌: 随机II期RE-AKT试验的结果

2024-07-011
OAAI
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI
Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial
2024-04-050
PRE
BCL2 expression is enriched in AR-independent advanced prostate cancer
2023-06-021
PRE
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer (vol 83, pg 224, 2023)

B7-H3作为晚期前列腺癌的治疗靶点 (第83卷,224页,2023页)

2023-06-011
OA
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

转移性去势抵抗性前列腺癌的免疫标志物

2022-12-0114
PRE
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

guadecitabine (SGI-110) 联合pembrolizumab治疗实体瘤患者的1期剂量递增研究

2022-06-1826
OAAI
Targeting radioresistance and replication fork in cancer
2022-05-094
OA
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
2021-08-0131
OAAI
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Toparp-b试验中与PARP抑制剂在前列腺癌中获益相关的生物标志物

2021-05-2799
OAAI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
2021-02-0186
OAAI
Elucidating Durable Responses to Immune Checkpoint Inhibition
2020-10-012
PREAI